Ovid Therapeutics Inc. (OVID): Price and Financial Metrics

Ovid Therapeutics Inc. (OVID): $3.64

0.03 (+0.83%)

POWR Rating

Component Grades








Add OVID to Watchlist
Sign Up

Industry: Biotech




#108 of 359

in industry

OVID Price/Volume Stats

Current price $3.64 52-week high $4.14
Prev. close $3.61 52-week low $1.40
Day low $3.40 Volume 108,600
Day high $3.68 Avg. volume 172,755
50-day MA $3.60 Dividend yield N/A
200-day MA $2.98 Market Cap 256.99M

OVID Stock Price Chart Interactive Chart >


  • OVID scores best on the Sentiment dimension, with a Sentiment rank ahead of 89.53% of US stocks.
  • The strongest trend for OVID is in Growth, which has been heading down over the past 179 days.
  • OVID's current lowest rank is in the Momentum metric (where it is better than 16.64% of US stocks).

OVID Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for OVID is 0 -- better than just 8.63% of US stocks.
  • OVID's price/sales ratio is 1,347.75; that's higher than the P/S ratio of 99.57% of US stocks.
  • As for revenue growth, note that OVID's revenue has grown -86.26% over the past 12 months; that beats the revenue growth of merely 1.65% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to OVID THERAPEUTICS INC, a group of peers worth examining would be VHC, ENTX, GANX, LXRX, and NAVB.
  • OVID's SEC filings can be seen here. And to visit OVID THERAPEUTICS INC's official web site, go to www.ovidrx.com.

OVID Valuation Summary

  • In comparison to the median Healthcare stock, OVID's EV/EBIT ratio is 134.68% lower, now standing at -4.3.
  • Over the past 78 months, OVID's price/earnings ratio has gone up 8.

Below are key valuation metrics over time for OVID.

Stock Date P/S P/B P/E EV/EBIT
OVID 2023-09-18 1344.7 2.4 -5.4 -4.3
OVID 2023-09-15 1408.5 2.5 -5.7 -4.5
OVID 2023-09-14 1362.3 2.4 -5.5 -4.3
OVID 2023-09-13 1295.0 2.3 -5.2 -4.1
OVID 2023-09-12 1295.0 2.3 -5.2 -4.1
OVID 2023-09-11 1241.7 2.2 -5.0 -3.9

OVID's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • OVID has a Quality Grade of C, ranking ahead of 59.21% of graded US stocks.
  • OVID's asset turnover comes in at 1.419 -- ranking 13th of 682 Pharmaceutical Products stocks.
  • QURE, ACER, and SCYX are the stocks whose asset turnover ratios are most correlated with OVID.

The table below shows OVID's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 1.419 1 -10.143
2021-03-31 1.963 1 -8.584
2020-12-31 0.184 1 18.535
2020-09-30 0.099 1 -10.445
2020-06-30 0.000 NA -8.770
2020-03-31 0.000 NA -6.119

OVID Price Target

For more insight on analysts targets of OVID, see our OVID price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.75 Average Broker Recommendation 1.5 (Moderate Buy)

Ovid Therapeutics Inc. (OVID) Company Bio

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company was founded in 2014 and is based in New York City, New York.

OVID Latest News Stream

Event/Time News Detail
Loading, please wait...

OVID Latest Social Stream

Loading social stream, please wait...

View Full OVID Social Stream

Latest OVID News From Around the Web

Below are the latest news stories about OVID THERAPEUTICS INC that investors may wish to consider to help them evaluate OVID as an investment opportunity.

Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in a panel presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26, 2023, at 9:55 a.m. ET in New York, New York. A live webcast of the Cantor Fitzgerald presentation can be accessed

Yahoo | September 20, 2023

Ovid Therapeutics to Participate in Upcoming September Investor Conferences

NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in two upcoming investor conferences. Citi’s 18th Annual BioPharma Conference – Ovid will participate on Thursday, September 7, 2023 in Boston, Massachusetts. The H.C. Wainwright 25th Annual Global Investment Conference – Ov

Yahoo | August 30, 2023

3 Very Promising Penny Stocks That Are Flying Under the Radar

Although the very concept of penny stocks to buy screams risk, these ideas just might be intriguing enough for speculators.

Josh Enomoto on InvestorPlace | August 16, 2023

Ovid Therapeutics (OVID) Reports Q2 Loss, Lags Revenue Estimates

Ovid Therapeutics (OVID) delivered earnings and revenue surprises of 14.29% and 17.58%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 4, 2023

Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates

Completed single ascending dose (SAD) portion of Phase 1 trial evaluating OV329, a potential next-generation GABA-aminotransferase inhibitor Executed equity investment and initiated collaboration with Graviton Bioscience to develop highly selective ROCK2 inhibitors for rare neurological conditionsExpanded scientific leadership team with appointments of Chief Scientific Officer and Chief Medical Officer Regulatory filings for soticlestat in Lennox-Gastaut syndrome and Dravet syndrome continue to

Yahoo | August 4, 2023

Read More 'OVID' Stories Here

OVID Price Returns

1-mo -7.96%
3-mo 6.74%
6-mo 27.72%
1-year 96.76%
3-year 30.00%
5-year 28.62%
YTD 95.70%
2022 -42.06%
2021 38.96%
2020 11.33%
2019 71.49%
2018 -75.48%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!